15-Deoxy-delta 12,14-prostaglandin J2 是脂肪细胞决定因子 PPAR 玛的配体
B M Forman1, P Tontonoz, J Chen
1Salk Institute for Biological Studies, La Jolla, California 92037, USA.
Cell
|December 1, 1995
概括
研究人员确定了15-deoxy-delta 12,14-prostaglandin J2作为脂肪生成的关键调节剂,同时作为PPAR玛配体和脂肪细胞发育的诱导剂. 这一发现突出了代谢健康的关键途径.
科学领域:
- 分子内分泌学分子内分泌学
- 细胞生物学 细胞生物学
- 代谢调节 代谢调节 代谢调节
背景情况:
- 脂肪细胞质量调节对于脊椎动物的平衡至关重要.
- 纤维细胞转化为脂肪细胞是由氧酶增殖器激活受体玛 (PPARγ) 表达的介导.
- 内生PPARγ配体的存在表明它在调节脂肪生成方面发挥了作用.
研究的目的:
- 为了识别激活PPAR反应元素的内源配体.
- 为了研究这些配体在脂肪生成中的作用.
- 探索涉及PPARγ在脂肪细胞发育和葡萄糖平衡中的信号通路.
主要方法:
- 对PPAR反应元件激活的阿拉基多酸代谢物的查.
- 评估已识别的化合物的诱导脂肪生成的能力.
- 研究 thiazolidinedione 药物与 PPARγ 的结合.
主要成果:
- 15-deoxy-delta12,14-prostaglandin J2被确定为PPARγ配体和脂肪生成的诱导剂.
- thiazolidinedione 抗糖尿病药物也与 PPARγ 结合,并调节脂肪细胞的发育.
- 前列腺素和 thiazolidinedione 都使用一个共同的 PPARγ 信号通路.
结论:
- PPARγ及其内源配体在脂肪细胞发育和葡萄糖平衡中发挥着关键作用.
- PPARγ信号通路是代谢障碍干预的关键目标.
- 这项研究阐明了代谢调节的一个基本机制.
相关概念视频
01:09GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
01:25cAMP-dependent Protein Kinase Pathways
Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
01:31Transducer Mechanism: Nuclear Receptors
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...